Yuhan Corporation to pay $325M to in-license preclinical HER2 candidate
Yuhan Corporation said Tuesday that it is paying up to $325 million to fellow South Korean biotech J INTS Bio to license an oral non-small cell lung cancer drug.
The deal is for JIN-A04, a preclinical oral tyrosine kinase inhibitor targeting NSCLC with HER2 exon 20 mutations.
J INTS Bio said back in February that preclinical data on the molecule would be presented at the American Association for Cancer Research’s annual meeting in Orlando, saying that the molecule “showed potent efficacy against HER2 Exon20 insertion mutant NSCLC cell lines, and in-vivo mouse models using HER2 Exon20 insertion mutant cell lines significant tumor regression was demonstrated.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.